In the wake of the increase in Current Liabilities in the fourth quarter 2018, Quick Ratio fell to 1.19 above Dna Testing Centers Corp average.

Within In Vitro & In Vivo Diagnostic Substances industry 15 other companies have achieved higher Quick Ratio than Dna Testing Centers in fourth quarter 2018. While Quick Ratio total ranking has improved so far during the Q4 2018 to 1657, from total ranking in the fourth quarter 2017 at 4460.

Explain Quick Ratio?
How much Cash & cash equivalents DNAT�s has?
What are DNAT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

DNAT Quick Ratio	(Dec 31 2018) Q4	(Dec 31 2017) Q4	(Sep 30 2017) Q3	(Jun 30 2017) Q2	(Mar 31 2017) Q1
Y / Y Current Liabilities Change	52.11 %	6.98 %	-65.49 %	-57.91 %	-21.15 %
Y / Y Cash & cash equivalent Change	1742.13 %	2099.58 %	2600.73 %	158.53 %	-67.36 %
Quick Ratio MRQ	1.19	2.53	3.81	0.33	0.1
DNAT's Total Ranking	# 1657	# 4460	#	#	#
Seq. Current Liabilities Change	20.88 %	52.76 %	-4.87 %	-13.41 %	-14.98 %
Seq. Cash & cash equivalent Change	-43.27 %	1.42 %	991.81 %	193.28 %	-32.27 %

Quick Ratio fourth quarter 2018 Company Ranking
Within:	No.
In Vitro & In Vivo Diagnostic Substances Industry	# 16
Healthcare Sector	# 588
Overall Market	# 1657

Quick Ratio Statistics
High	Average	Low
3.81	0.83	0.03
(Sep 30 2017)		(Dec 31 2015)

Financial Statements
Dna Testing Centers's Current Liabilities	$ 0 Millions	Visit DNAT's Balance sheet
Dna Testing Centers's Cash & cash equivalent	$ 0 Millions	Visit DNAT's Balance sheet
Source of DNAT's Sales		Visit DNAT's Sales by Geography

Cumulative Dna Testing Centers's Quick Ratio

DNAT's Quick Ratio for the trailling 12 Months

DNAT Quick Ratio	(Dec 31 2018) 12 Months	(Dec 31 2017) 12 Months	(Sep 30 2017) 12 Months	(Jun 30 2017) 12 Months	(Mar 31 2017) 12 Months
Y / Y Current Liabilities TTM Growth	-32.5 %	-42.69 %	-35.24 %	32.18 %	144.07 %
Y / Y Cash & cash equivalent TTM Growth	1689.84 %	897.46 %	584.94 %	-15.39 %	-85.06 %
Quick Ratio TTM	1.88	1.7	0.95	0.12	0.07
Total Ranking TTM	# 4906	# 4819	#	#	#
Seq. Current Liabilities TTM Growth	13.2 %	2.12 %	-28.79 %	-18 %	-3.89 %
Seq. Cash & cash equivalent TTM Growth	25.46 %	82.82 %	467.56 %	37.49 %	-30.08 %

Quick ratio ranking by company, industry and sector >> Back to DNAT Financial Strength Comparisons >> Go to Compare DNAT Quick Ratio to its Competitors

On the trailing twelve months basis DNAT Cash & cash equivalent more than doubled by 1742.13 % in Q4 2018 year on year, faster than Current Liabilities, this led to increase in in Dna Testing Centers's Quick Ratio to 1.88, above DNAT average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 21 other companies have achieved higher Quick Ratio than Dna Testing Centers. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2017 from 4819 to 4906.

Explain Quick Ratio?
How much Cash & cash equivalents DNAT�s has?
What are DNAT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the In Vitro & In Vivo Diagnostic Substances Industry	# 22
Healthcare Sector	# 895
Within the Market	# 4906

trailing twelve months Quick Ratio Statistics
High	Average	Low
1.88	0.54	0.07
(Dec 31 2018)		(Mar 31 2017)

Companies with similar Quick Ratio in the quarter ending Dec 31 2018, within In Vitro & In Vivo Diagnostic Substances Industry	Quick Ratio	Dec 31 2018 MRQ Cash & cash equivalent	Dec 31 2018 MRQ Current Liabilities
Meridian Bioscience Inc	2.97	$ 61.523 Millions	$ 20.690 Millions
Qc Technologies Inc	2.76	$ 5.455 Millions	$ 1.974 Millions
Lantheus Holdings Inc	1.81	$ 113.401 Millions	$ 62.543 Millions
Insight Molecular Diagnostics Inc	1.44	$ 8.034 Millions	$ 5.561 Millions
Myriad Genetics Inc	1.42	$ 180.600 Millions	$ 127.100 Millions
Navidea Biopharmaceuticals Inc	1.31	$ 4.275 Millions	$ 3.258 Millions
Biomerica Inc	1.30	$ 1.205 Millions	$ 0.928 Millions
Dna Testing Centers Corp	1.19	$ 0.047 Millions	$ 0.040 Millions
Immucell Corporation	0.98	$ 2.521 Millions	$ 2.565 Millions
Heska Corporation	0.51	$ 13.389 Millions	$ 26.363 Millions
Trinity Biotech Plc	0.36	$ 31.980 Millions	$ 89.619 Millions
Quidelortho Corp	0.33	$ 43.695 Millions	$ 130.980 Millions

Date modified: 2026-08-30T10:51:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.